Press releases
These press releases are intended for journalists and analysts/investors.
-
GSK's parting gifts to local community
GSK is making generous donations to local educational facilities in recognition of the community in which it has played a key role
-
GSK and Sun Pharma complete Opiates transaction
GlaxoSmithKline (GSK) and Sun Pharma have successfully completed the transfer of GSK’s Australian Opiates business that was acquired
-
Pharmacy Level Recall - Bactroban® Cream (mupirocin calcium 2%) and Bactroban® Nasal Ointment (mupirocin calcium 2%)
GSK Australia, in consultation with the Therapeutic Goods Administration (TGA), is initiating a pharmacy level recall of five batches
-
Update on supply of Zovirax Ophthalmic Ointment (aciclovir 3%)
Zovirax Ophthalmic Ointment (aciclovir 3%) is impacted by an ongoing global supply constraint with no confirmed resupply date in Australia
-
GSK Australia releases 2014 Responsible Business Report
GSK Australia and New Zealand have published the third annual responsible business report, outlining key achievements in health, community
-
INTERNATIONAL MEN’S HEALTH WEEK 2015: Sam Newman exposes neglected men’s health issue
Australian campaign focuses on enlarged prostates
-
GSK Australia launches new vaccination picture book for Aboriginal and Torres Strait Islanders
GSK Australia has a new immunisation resource for Aboriginal and Torres Strait Islanders this month to encourage families to be proactive
-
GSK granted $1 million by Federal Government for advanced manufacturing project in Boronia
GSK Australia is a recipient of a grant through of the Federal Government’s Manufacturing Transition Programme worth AUD$1 million
-
GSK Australia Reports 2014 results to ASIC
GlaxoSmithKline (GSK) Australia reported to the Australian Securities and Investment Commission (ASIC) sales revenue of $906m in 2014
-
GSK Award for Research Excellence opens
Nominations for GSK’s Award for Research Excellence (ARE) open today for the 35th year running
-
Supply update: Fluarix Tetra and Fluarix
GSK advises supply of new quadrivalent (four-strain) influenza vaccine, Fluarix® Tetra, recently launched in Australia
-
GSK discloses payments to Australian healthcare professionals in 2014
In 2014, GSK Australia made payments totalling $3,466,951 to healthcare professionals (HCPs) and health-related organisations
-
GSK responds to devastation in Vanuatu
GSK provides £50,000 donation to Save the Children to support relief efforts following Tropical Cyclone Pam
-
Sun Pharma to buy GSK’s Opiates business in Australia
The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria)
-
GSK completes major three-part transaction with Novartis
GlaxoSmithKline plc (LSE/NYSE: GSK) announces that its three-part transaction with Novartis has completed today
-
Supply update: Zovirax Ophthalmic Ointment (aciclovir 3%) (1)
Regrettably, Zovirax Ophthalmic Ointment (aciclovir 3%) continues to be impacted by a global supply constraint
-
GSK statement on affordability of vaccines in developing countries
More children from the world’s poorest countries are being vaccinated against more diseases than ever before
-
Adelaide Hills Bushfires: Donation of asthma medication
GSK has responded to the South Australian bushfire emergency by providing eight pharmacies in the Adelaide Hills fire affected areas
-
Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS)
-
Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have welcomed news that Anoro Ellipta (umeclidinium/vilanterol) will be reimbursed
